These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8671791)

  • 61. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
    Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
    J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation.
    Min DI; Perry PJ; Chen HY; Hunsicker LG
    Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Analysis of the defect and beneficial effect of fish-oil.
    Levi M; Wilmink J; Büller HR; Surachno J; ten Cate JW
    Transplantation; 1992 Dec; 54(6):978-83. PubMed ID: 1465791
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction?
    Dimény E; Fellström B
    Nephrol Dial Transplant; 1997 Jan; 12(1):21-4. PubMed ID: 9027767
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regulators of fibrynolysis in plasma of kidney transplant recipients.
    Perkowska A; Elhasade A; Gaciong Z; Durlik M; Placha G; Galazka Z; Lao M
    Transplant Proc; 2002 Mar; 34(2):585-8. PubMed ID: 12009632
    [No Abstract]   [Full Text] [Related]  

  • 67. Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor.
    Berger CE; Kröner A; Stiegler H; Erdel M; Haas OA; Engel A
    Clin Orthop Relat Res; 2002 Apr; (397):342-9. PubMed ID: 11953626
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiovascular effects of an immunosuppressive agent cyclosporin A.
    Sakamoto H; Kurabayashi M
    Int J Immunopathol Pharmacol; 2000; 15(2):75-79. PubMed ID: 12590868
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Unveiling the Incidence and Graft Survival Rate in Kidney Transplant Recipients With
    Hsiung CY; Chen HY; Wang SH; Huang CY
    Transpl Int; 2024; 37():12168. PubMed ID: 38323071
    [No Abstract]   [Full Text] [Related]  

  • 70. Successful salvage of allograft dysfunction triggered by transplant renal vein thrombosis immediately after kidney transplantation: a case report.
    Hori S; Miyamoto T; Sakamoto K; Shimizu T; Ichikawa K; Morizawa Y; Gotoh D; Nakai Y; Miyake M; Yoneda T; Tanaka N; Yoshida K; Fujimoto K
    Int J Nephrol Renovasc Dis; 2018; 11():321-327. PubMed ID: 30538528
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Thrombotic microangiopathy after renal transplantation: Current insights in
    Abbas F; El Kossi M; Kim JJ; Sharma A; Halawa A
    World J Transplant; 2018 Sep; 8(5):122-141. PubMed ID: 30211021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern.
    Benza RL; Cavender MA; Barchue J; Tallaj JA; Bourge RC; Kirklin JK; Coffey CS
    J Heart Lung Transplant; 2007 May; 26(5):494-7. PubMed ID: 17449419
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of cyclosporine on regulators of fibrinolysis in plasma from renal allograft recipients.
    Elhasade AS; Perkowska A; Paczek L; Rowiński W; Soluch L; Szmidt J; Gałazka Z; Gaciong Z
    Ann Transplant; 1998; 3(1):13-8. PubMed ID: 9869892
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients.
    van den Dorpel MA; Veld AJ; Levi M; ten Cate JW; Weimar W
    Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1555-8. PubMed ID: 10364089
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation.
    Lewis RM
    Kidney Int Suppl; 1995 Dec; 52():S75-8. PubMed ID: 8587289
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fibrinolysis in chronic renal failure, dialysis and renal transplantation.
    Opatrný K; Zemanová P; Opatrná S; Vít L
    Ann Transplant; 2002; 7(1):34-43. PubMed ID: 12221902
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients.
    Verpooten GA; Cools FJ; Van der Planken MG; Bedert LC; Claes R; Van Gaal LF; De Broe ME
    Nephrol Dial Transplant; 1996 Feb; 11(2):347-51. PubMed ID: 8671791
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
    Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
    Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.